Archive for October, 2011
« Previous Entries Next Entries »US FDA grants approval to Neuralstem to dose patients in cervical region in … – pharmabiz.com
Saturday, October 29th, 2011
US FDA grants approval to Neuralstem to dose patients in cervical region in …pharmabiz.comThe trial is under the direction of Principal Investigator, Eva Feldman, MD, PhD, director of the A Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, and Jonathan D Glass, …
Whodunit by Jack Batten – Toronto Star
Saturday, October 29th, 2011Whodunit by Jack BattenToronto StarIn his worst, most hypochondrial worrying, he's afraid the dizziness marks the first faint signal of amyotrophic lateral sclerosis (Lou Gehrig's disease in North America). Sejer lists in his mind famous sufferers from ALS. Mao Zedong, Stephen Hawking. …and more »
David Meeker, Member of Prize4Life’s Board of Directors, Named Genzyme CEO – DigitalJournal.com (press release)
Friday, October 28th, 2011David Meeker, Member of Prize4Life's Board of Directors, Named Genzyme CEODigitalJournal.com (press release)The organization aims to use prizes to bring new minds and new money into the fight against ALS and focus efforts on specific outcomes that will bridge the gap between academic research and the development of treatments and a cure.and more »
Sands of time, a chronicle of courage – BCLocalNews
Friday, October 28th, 2011Sands of time, a chronicle of courageBCLocalNewsMike was working full-time as a nurse at Riverview Hospital in Port Coquitlam, and researched his symptoms. The possibilities were not good. “I was hoping for Lyme disease or MS,” he says. “Anything but ALS.” After visiting four doctors for four …
Biogen Idec’s CEO Discusses Q3 2011 Results – Earnings Call Transcript – Seeking Alpha
Friday, October 28th, 2011Biogen Idec's CEO Discusses Q3 2011 Results – Earnings Call TranscriptSeeking AlphaMoving on to the rest of the pipeline, we completed enrollment for EMPOWER, the first global Phase III study of dexpramipexole, for treatment of ALS or Lou Gehrig's disease. This was the fastest enrolling trial in Biogen Idec's history, …and more »
Neuralstem’s treatment for Lou Gehrig’s disease advances – Gazette.Net: Maryland Community News Online
Friday, October 28th, 2011Neuralstem's treatment for Lou Gehrig's disease advancesGazette.Net: Maryland Community News OnlineNeuralstem has won federal approval to begin administering stem cell injections in the upper backs of patients in the phase 1 safety trial of its treatment for amyotrophic lateral sclerosis. Previously, the Food and Drug Administration had approved …
Cytokinetics, Incorporated Reports Third Quarter 2011 Financial Results – Newsday (subscription)
Thursday, October 27th, 2011Cytokinetics, Incorporated Reports Third Quarter 2011 Financial ResultsNewsday (subscription)Skeletal Muscle Contractility CK-2017357 — Cytokinetics recently concluded enrollment of patients in Part A of its Phase II, multiple fixed-dose clinical trial of CK-2017357 in amyotrophic lateral sclerosis (ALS) patients. …Cytokinetics, Incorporated Reports Third Quarter 2011 Financial ResultsMarketWatch (press release)Cytokinetics, Incorporated Reports Third Quarter 2011 Financial ResultsMarketwire [...]
Cytokinetics, Incorporated Reports Third Quarter 2011 Financial Results – MarketWatch (press release)
Thursday, October 27th, 2011Cytokinetics, Incorporated Reports Third Quarter 2011 Financial ResultsMarketWatch (press release)Additional information about ATOMIC-AHF can be found at www.clinicaltrials.gov — Cytokinetics recently concluded enrollment of patients in Part A of its Phase II, multiple fixed-dose clinical trial of CK-2017357 in amyotrophic lateral sclerosis (ALS) …and more »
Cytokinetics, Incorporated Reports Third Quarter 2011 Financial Results – Marketwire (press release)
Thursday, October 27th, 2011Cytokinetics, Incorporated Reports Third Quarter 2011 Financial ResultsMarketwire (press release)Cytokinetics recently concluded enrollment of patients in Part A of its Phase II, multiple fixed-dose clinical trial of CK-2017357 in amyotrophic lateral sclerosis (ALS) patients. Part A was designed to evaluate the safety, tolerability, …Cytokinetics, Incorporated Reports Third Quarter 2011 Financial ResultsMarketWatch (press release)all 5 news [...]
Chardan Capital Markets Initiates Research Coverage of Adeona – Sacramento Bee
Thursday, October 27th, 2011Chardan Capital Markets Initiates Research Coverage of AdeonaSacramento BeeAdeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products …and more »
« Previous Entries Next Entries »